Skip to content




Sort by
Previous Page Page 1 of 1 Next Page
  1. Content type: Research

    Patients with cancer treatment-related cardiotoxicity, which may manifest as heart failure (HF), can present with dyspnea. Nurses frequently assess, triage and offer self-care strategies to patients experienci...

    Authors: F. Kelly, S. L. Carroll, M. Carley, S. Dent, R. Shorr, J. Hu, R. Morash and D. Stacey

    Citation: Cardio-Oncology 2017 3:7

    Published on:

  2. Content type: Research

    Cardiotoxicity from anticancer therapy affects heart function and structure. Cardiotoxicity can also lead to accelerated development of chronic diseases, especially in the presence of risk factors.

    Authors: Robyn A. Clark, Tania S. Marin, Narelle M. Berry, John J. Atherton, Jonathon W. Foote and Bogda Koczwara

    Citation: Cardio-Oncology 2017 3:6

    Published on:

  3. Content type: Research

    Antineoplastic therapy with the tyrosine kinase inhibitor pazopanib in patients with advanced/metastatic renal cell carcinoma (mRCC) has been associated with hypertension (HTN), cardiomyopathy, and cardiac dys...

    Authors: Daniel Pinkhas, Thai Ho and Sakima Smith

    Citation: Cardio-Oncology 2017 3:5

    Published on:

  4. Content type: Research

    Proteasome inhibitors (PI) bortezomib and carfilzomib are cornerstone therapies for multiple myeloma. Higher incidence of cardiac adverse events (CAEs) has been reported in patients receiving carfilzomib. Howe...

    Authors: John H. Chen, Daniel J. Lenihan, Sharon E. Phillips, Shelton L. Harrell and Robert F. Cornell

    Citation: Cardio-Oncology 2017 3:4

    Published on:

  5. Content type: Review

    Atrial fibrillation (AF) is frequently observed in patients being treated for cancer and can lead to increased morbidity and mortality in this population. With the use of newer, targeted cancer therapies, seve...

    Authors: Aarti Asnani, Anastasia Manning, Moussa Mansour, Jeremy Ruskin, Ephraim P. Hochberg and Leon M. Ptaszek

    Citation: Cardio-Oncology 2017 3:2

    Published on:

  6. Content type: Research

    Sinus bradycardia is frequently observed in patients treated with crizotinib, a receptor tyrosine kinase inhibitor used for the treatment of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung canc...

    Authors: Zhushan Zhang, Tai-Qin Huang, Igor Nepliouev, Hengtao Zhang, Adam S. Barnett, Paul B. Rosenberg, Sai-Hong I. Ou and Jonathan A. Stiber

    Citation: Cardio-Oncology 2017 3:1

    Published on:

  7. Content type: Short communication

    Due to aging of the population and cardiotoxic cancer treatment, there is an increasing group of patients with cancer and co-morbid cardiovascular disease (CVD). In order to find a balance between the risk of ...

    Authors: Dounya Schoormans, Susanne S. Pedersen, Susanne Dalton, Nina Rottmann and Lonneke van de Poll-Franse

    Citation: Cardio-Oncology 2016 2:9

    Published on:

  8. Content type: Short communication

    The treatment of Acute Myeloid Leukemia (AML) leads to several functional limitations. Especially cardiac burden following cardiotoxic chemotherapy, which limits exercise and competitive sport in the long-term...

    Authors: Pia von Korn, Manfred Vogt, Renate Oberhoffer, Peter Ewert and Jan Müller

    Citation: Cardio-Oncology 2016 2:8

    Published on:

  9. Content type: Research

    The presence and burden of coronary artery calcium (CAC) is a strong predictor of cardiovascular events. In an effort to gain insight into the utility of CAC for coronary artery disease (CAD) screening in canc...

    Authors: Alison M. Brann, Charlotte J. Bai, John F. Hibbeln, Kim A. Williams and Tochi M. Okwuosa

    Citation: Cardio-Oncology 2016 2:7

    Published on:

  10. Content type: Research

    Electrocardiographic changes may manifest in patients with pericardial effusions. PR segment changes are frequently overlooked, but when present, can provide diagnostic significance. The diagnostic value of PR...

    Authors: M. Ahluwalia, R. O’Quinn, B. Ky, D. Callans, J. Kucharczuk and J. R. Carver

    Citation: Cardio-Oncology 2016 2:6

    Published on:

  11. Content type: Review

    The diagnosis and management of cardiovascular complications have become a clinical concern for oncologists, cardiologists, surgeons, interventional radiologists, radiation therapy physicians, internists, nurs...

    Authors: Sergio Barros-Gomes, Joerg Herrmann, Sharon L. Mulvagh, Amir Lerman, Grace Lin and Hector R. Villarraga

    Citation: Cardio-Oncology 2016 2:5

    Published on:

  12. Content type: Research

    Doxorubicin (DOX) is a very effective anticancer medication that is commonly used to treat hematological malignancies and solid tumors. Nevertheless, DOX is known to have cardiotoxic effects that may lead to c...

    Authors: Beshay N. Zordoky, M. Judith Radin, Lois Heller, Anthony Tobias, Ilze Matise, Fred S. Apple, Sylvia A. McCune and Leslie C. Sharkey

    Citation: Cardio-Oncology 2016 2:4

    Published on:

  13. Content type: Review

    The cardiotoxicity of doxorubicin is becoming an interdisciplinary point of interest given a growing population of cancer survivors. The complex and not completely understood pathogenesis of this complication ...

    Authors: Antonella De Angelis, Konrad Urbanek, Donato Cappetta, Elena Piegari, Loreta Pia Ciuffreda, Alessia Rivellino, Rosa Russo, Grazia Esposito, Francesco Rossi and Liberato Berrino

    Citation: Cardio-Oncology 2016 2:2

    Published on:

  14. Content type: Review

    New anti-cancer drugs that inhibit the vascular endothelial growth factor (VEGF) signaling pathway are highly effective in the treatment of solid tumors, however concerns remain regarding their cardiovascular ...

    Authors: Yishay Wasserstrum, Ran Kornowski, Pia Raanani, Avi Leader, Oren Pasvolsky and Zaza Iakobishvili

    Citation: Cardio-Oncology 2015 1:6

    Published on:

  15. Content type: Review

    Tyrosine kinase inhibitors (TKIs) have revolutionized the management and outcomes of chronic myeloid leukemia (CML) patients. Improved disease control and prolonged life expectancy now mandate focus on improvi...

    Authors: Oren Pasvolsky, Avi Leader, Zaza Iakobishvili, Yishay Wasserstrum, Ran Kornowski and Pia Raanani

    Citation: Cardio-Oncology 2015 1:5

    Published on:

  16. Content type: Review

    Afatinib is an oral irreversible ErbB family blocker that targets epidermal growth factor receptor (EGFR/ErbB1), human epidermal growth factor receptor 2 (HER2/ErbB2), and HER4 (ErbB4) and is approved for the ...

    Authors: Michael S. Ewer, Kalpesh Patel, Dennis O’Brien and Robert M. Lorence

    Citation: Cardio-Oncology 2015 1:3

    Published on:

  17. Content type: Research

    Subacute cardiotoxicity, consisting of acute myocyte damage and associated left ventricular dysfunction, occurs early during anthracycline therapy. We investigated the impact of myocardial dysfunction, defined...

    Authors: Olga H. Toro-Salazar, Eileen Gillan, Joanna Ferranti, Andrea Orsey, Karen Rubin, Shailendra Upadhyay, Wojciech Mazur and Kan N. Hor

    Citation: Cardio-Oncology 2015 1:1

    Published on:

Previous Page Page 1 of 1 Next Page

2016 Journal Metrics

  • Speed
    16 days from submission to first decision
    14 days from acceptance to publication

    1308.0 Usage Factor